Direkt zum Inhalt
Merck
  • Generation of three human induced pluripotent stem cell (iPSC) lines from three patients with Dravet syndrome carrying distinct SCN1A gene mutations.

Generation of three human induced pluripotent stem cell (iPSC) lines from three patients with Dravet syndrome carrying distinct SCN1A gene mutations.

Stem cell research (2019-08-11)
Jens Schuster, Ambrin Fatima, Maria Sobol, Feria Hikmet Norradin, Loora Laan, Niklas Dahl
ZUSAMMENFASSUNG

Dravet syndrome (DS) is a childhood epilepsy syndrome caused by heterozygous mutations in the SCN1A gene encoding voltage-gated sodium channel Nav1.1. We generated iPSCs from fibroblasts of three DS patients carrying distinct SCN1A mutations (c.5502-5509dupGCTTGAAC, c.2965G>C and c.651C>G). The iPSC lines were genetically stable and each line retained the SCN1A gene mutation of the donor fibroblasts. Characterization of the iPSC lines confirmed expression of pluripotency markers, absence of exogenous vector expression and trilineage differentiation potential. These iPSC lines offer a useful resource to investigate the molecular mechanisms underlying Nav1.1 haploinsufficiency and for drug development to improve treatment of DS patients.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Accutase® -Lösung, sterile-filtered, suitable for cell culture
Sigma-Aldrich
4′,6-Diamidin-2-phenylindol -dihydrochlorid, powder, BioReagent, suitable for cell culture, ≥98% (HPLC and TLC), suitable for fluorescence
Sigma-Aldrich
Anti-NANOG Antibody, clone 7F7.1, clone 7F7.1, from mouse
Sigma-Aldrich
Zink-Isopropylsulfinat, 95%